Maxygen Boosted by Roche Milestone

The collaboration aims to develop improved interferon alpha protein therapeutics to treat hepatitis C virus (HCV) and hepatitis B virus (HBV) infections. Maxygen and Roche are currently completing late stage preclinical studies and good manufacturing practices (GMP) manufacturing and are on track to file an investigational new drug (IND) application in preparation for Phase I clinical trials in 2006.

Pharmaceutical Business Review (http://www.pharmaceutical-business-review.com/article_news.asp?guid=D07E4B3D-7C17-46AD-B7DF-6D8A62CB3662)